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Abstract
Interstitial pneumonia (IP) refers to involvement of the lung parenchyma by varying degrees 
of inflammation and fibrosis, in contrast to airspace disease typically seen in bacterial pneu-
monia. IP lies in the center of a heterogenous group of diffuse interstitial lung diseases (ILDs), 
either idiopathic or linked to underlying disorders. One of the major categories of disorders 
frequently associated with IP is a connective tissue disease (CTD), in which autoimmune-
mediated tissue injury leads to multiple organ impairment. Today, IP represents the most 
critical pulmonary complication in CTD, resulting in significant morbidity and mortality. 
Despite growing understanding of the pathology of IPs, as well as the accumulating knowl-
edge from both basic and clinical studies of CTDs, the pathogenesis of CTD-associated IP 
remains unclear. This chapter will provide an overview of the general understanding of ILD 
and illustrate the current state of knowledge on IP associated with CTD, in order to fully 
comprehend the entirety of its complex pictures. Moreover, we will propose a new insight 
into the immune pathogenesis of CTD-IP by presenting evidence which robustly indicates 
that T cells trigger initial development of IP in polymyositis/dermatomyositis, suggesting 
potential approaches for controlling such particular T cells in therapeutic interventions for IP.
Keywords: interstitial pneumonia, interstitial lung disease, connective tissue disease, 
polymyositis/dermatomyositis, T lymphocyte, T cell receptor, antigen-driven 
mechanisms
1. Introduction
The term “Interstitial pneumonia” (IP) is used to describe noninfectious, inflammatory lung 
disorders characterized by the histologic abnormalities with diffuse interstitial fibrosis involv-
ing alveolar walls. In contrast to airspace disease typically seen in bacterial pneumonia, IP 
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refers to involvement of the lung parenchyma by varying combination of fibrosis and inflam-
mation [1, 2]. IP is included in the “interstitial lung disease” (ILD), i.e., a heterogenous group of 
diffuse parenchymal lung disorders, either idiopathic or associated with injurious or inflam-
matory causes, in which the major site of damage is the lung interstitium [3]. Customarily, the 
designations IP and ILD are sometimes used interchangeably. To be accurate, however, ILD 
comprises a broader range of lung diseases which involves the pulmonary interstitium, 
including drug-induced pneumonitis and eosinophilic pneumonia, etc. Primarily, IP refers to 
the particular disease entities which belong to idiopathic interstitial pneumonia (IIP) defined 
by the 2002 and 2012 American Thoracic Society/European Respiratory Society (ATS/ERS) 
classification [1–4]. IIP was categorized into several forms of IPs, afterward each histopatho-
logic pattern of which has been applied to the ILD associated with underlying diseases as 
well; the details of these will be described later.
From the pathophysiological perspective, the pulmonary interstitium consists of area with mini-
mal connective tissue matrix between the capillaries and the alveolar space that allows close 
apposition of gas and blood flow leading to efficient gas exchange. If any injury from a specific 
exposure of chemicals or proteins, an autoimmune-mediated inflammation, or unknown etiol-
ogy occurs and persists, the lung may respond to the damage by repairing process with increased 
interstitial tissue resulting in histological remodeling. Thus, ILDs may cause serious pulmonary 
dysfunction, which is often associated with substantial morbidity and poor prognosis.
ILD comprises a variety of disorders with diverse backgrounds. A part of ILD has no identifi-
able underlying cause and is regarded as idiopathic, whereas it is often associated with a spe-
cific environmental exposure or with underlying diseases such as connective tissue disease 
(CTD) [1]. The CTDs are a group of systemic, inflammatory, autoimmune disorder, in which 
autoimmune-mediated tissue injury leads to multiple organ impairment including respira-
tory system. Today, IP or ILD is one of the most serious pulmonary complications associated 
with CTDs, resulting in significant morbidity and mortality [5]. Despite growing, understand-
ing of the details of pathology in IPs, as well as accumulating evidences which support an 
association between IP with CTD and the presence of autoantibodies, the pathogenesis of 
CTD-associated IP remains unclear.
During the last years, we have been exploring the possible involvement of adaptive immunity 
in the pathogenesis of IP associated with CTDs, and we found intriguing evidence which 
strongly suggests a pivotal role of T cells in triggering the development of pulmonary alveoli-
tis through antigen-driven immune responses in early stage IP [6, 7]. In this chapter, first, we 
will overview the current concepts of ILD as well as CTD-associated IP, in order to compre-
hend the whole picture including pathological features. Then, novel findings demonstrated 
in our recent studies of IP associated with polymyositis/dermatomyositis will be discussed.
2. Understanding of interstitial lung disease
2.1. The concept of interstitial lung disease
ILD, also known as diffuse parenchymal lung disease (DPLD), is a generic term encompassing 
a broad spectrum of heterogenous lung disorders, either idiopathic or associated with injurious 
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or inflammatory causes, in which the major site of damage is the lung interstitium [1–3]. 
Because of the nature of DPLD which involves the interstitium, the ILDs share common radio-
logic, pathologic, and clinical manifestations. Clinically, exertional dyspnea and nonproductive 
cough are most common manifestations. Bilateral inspiratory fine crackles, most prominent at 
the lung bases, are usually audible on auscultation. Clubbed fingers characterized by hyper-
trophy and enlargement of the distal phalanges of the hands are often seen and reported in 
30–50% of patients with IPF (idiopathic pulmonary fibrosis; to be mentioned later) [8]. Clinical 
features suggestive of rheumatic disorders, such as arthralgia, Raynaud’s phenomenon, and 
skin manifestations, might be observed in the setting of an underlying CTD. The plain chest 
radiograph shows reduced lung volumes with bilateral reticular or reticulonodular opacities. 
High-resolution computed tomography (HRCT), which offers better definition of the charac-
teristic details of lung parenchyma, can reveal usually bilateral, peripheral, and basilar pre-
dominant abnormalities with reticulonodular infiltrates, often with honeycombing and cystic 
changes by IP type to be described later. Although chest radiography is less useful than HRCT 
in the detailed evaluation, it is helpful for evaluating disease distribution and its serial change 
during patient follow up [8]. Physiologically, the patients demonstrate diminished diffusion 
capacity (decreased DLco) with usually restrictive impairment in pulmonary function tests.
2.2. Classification of interstitial lung disease
Figure 1 provides an overview of the classification of ILD, based on the 2002 and 2012 the 
American Thoracic Society/European Respiratory Society (ATS/ERS) classification statements 
[1–3]. Briefly, ILDs consist of disorders of known causes (underlying diseases, environmental, 
or drug related) as well as disorders of unknown causes. The latter include idiopathic inter-
stitial pneumonias (IIPs), granulomatous lung disorders (e.g., sarcoidosis), and other forms 
of orphan ILD, i.e., lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocy-
tosis/histiocytosis X (PLCH), and eosinophilic pneumonia. Thus, the ILDs comprise a variety 
of disorders with diverse backgrounds. Whereas a part of ILD has no identifiable underlying 
cause, often, it is associated with a specific environmental exposure or with underlying CTD 
[5]. ILDs are classified according to specific clinical, radiological, and histopathological fea-
tures. The ILDs, however, frequently have similar clinical features. As ILDs are often uneasy 
to distinguish each other, the updated guidelines in the 2013 ATS/ERS classification state-
ment underlined the importance of multidisciplinary diagnosis (MDD) facilitated by profes-
sional experts [2, 3]. Adequate presentation and discussion of clinical and radiological data 
are essential for an accurate MDD. Among diagnostic modalities, high-resolution computed 
tomography (HRCT) makes it possible to characterize ILD with great precision. Surgical lung 
biopsy also remains the gold standard for evaluation of ILD.
2.3. Classification of idiopathic interstitial pneumonia
As noted above, if ILD is found to have no association with specific causes, such as chemical 
exposure, underlying systemic diseases, or genetic causes, the disease is classified as “idio-
pathic interstitial pneumonia” (IIP). IIPs are a heterogenous group of nonneoplastic disorders 
involving damage to the lung parenchyma with varying patterns of inflammation and fibrosis. 
The interstitium includes the space between epithelial and endothelial basement membranes 
and is the primary site of injury in IIPs. Frequently affecting not only the interstitium, but IIPs 
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may also involve the airspace, peripheral airways, and vessels, along with their respective 
epithelial and endothelial linings [1, 2].
As shown in Figure 1, the IIPs are further categorized into “idiopathic pulmonary fibrosis” (IPF), 
“nonspecific interstitial pneumonia” (NSIP: further subdivided into cellular and fibrotic NSIP), 
“cryptogenic organizing pneumonia” (COP), “acute interstitial pneumonia” (AIP), “respiratory 
Figure 1. Classification of interstitial lung disease. Interstitial lung diseases (ILDs), also termed as diffuse parenchymal 
lung diseases (DPLDs), consist of disorders of known causes (connective tissue diseases, environmental, or drug related) 
as well as disorders of unknown cause. The latter include idiopathic interstitial pneumonias (IIPs), granulomatous lung 
disorders (e.g., sarcoidosis), and other forms of interstitial lung disease (ILD) including lymphangioleiomyomatosis 
(LAM), pulmonary Langerhans cell histiocytosis/histiocytosis X (PLCH), and eosinophilic pneumonia. The idiopathic 
interstitial pneumonias (IIPs) are further categorized as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial 
pneumonia (NSIP), cryptogenic organizing pneumnia (COP), acute interstitial pneumonia (AIP), respiratory bronchiolitis 
interstitial lung disease (RB-ILD), or desquamative interstitial pneumonia (DIP). Lymphoid interstitial pneumonia (LIP) 
is occasionally associated with other disease processes, such as connective tissue diseases or immunosuppression while 
idiopathic LIP is rare.
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bronchiolitis interstitial lung disease” (RB-ILD), or “desquamative interstitial pneumonia” (DIP) 
[1, 2]. “Lymphoid interstitial pneumonia” (LIP) is occasionally associated with other processes, 
such as connective tissue diseases or immunosuppression, while idiopathic LIP is rare. Among 
the IIPs, idiopathic pulmonary fibrosis (IPF) is the most common prototypic IIP. “Usual inter-
stitial pneumonia” (UIP) is the pathologic pattern of lung injury seen in IPF. Categorization of 
major IIP and corresponding histological patterns defining each entity are shown in Table 1 [2].
2.3.1. The importance of HRCT findings in the classification and diagnosis of interstitial lung disease
The ATS/ERS/JRS/ALAT 2011 guidelines for IPF have assigned a primary diagnostic role to 
HRCT, and the HRCT criteria outlined was the same as those in the revised guideline pub-
lished in 2015 [8–10]. The diagnosis of IPF should be based on the exclusion of other known 
causes of ILDs (environmental exposures, drugs, and CTDs) and presence of UIP on HRCT; 
UIP is characterized on HRCT by the presence of reticular abnormalities with subpleural 
and basal distribution, honeycombing with or without traction bronchiectasis, and absence of 
features inconsistent with UIP such as extensive ground-glass opacities, diffuse mosaic atten-
uation, profuse micronodules, and consolidations. Certain HRCT features predict histopatho-
logic patterns of the different forms of ILD. Table 2 outlines the classification of histological 
and corresponding radiological patterns defining each entity of IIP, which is also applicable 
to CTD-associated ILD, to be explained later [5, 11].
3. Clinical landscape of interstitial lung disease in connective tissue 
disease
The connective tissue disease (CTD) is a systemic, inflammatory, autoimmune disorder char-
acterized by immune-mediated multiple organ dysfunction. The category of CTD includes a 




Idiopathic pulmonary fibrosis (IPF) Usual interstitial pneumonia (UIP)
Idiopathic nonspecific interstitial pneumonia 
(NSIP)
Nonspecific interstitial pneumonia (NSIP)
Smoking-related 
IP*
Respiratory bronchiolitis-interstitial lung 
disease (RB-ILD)
Respiratory bronchiolitis-ILD (RB-ILD)
Desquamative interstitial pneumonia (DIP) Desquamative interstitial pneumonia (DIP)
Acute/subacute 
IP
Cryptogenic organizing pneumonia (COP) Organizing pneumonia (OP)
Acute interstitial pneumonia (AIP) Diffuse alveolar damage (DAD)
Definition of abbreviation: IP = interstitial pneumonia.
*Desquamative interstitial pneumonia can occasionally occur in nonsmokers.
Adapted from Travis et al. [2].
Table 1. Categorization of major IIP.
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variety of diseases: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic 
sclerosis (Scleroderma, SSc), polymyositis/dermatomyositis (PM/DM), and a group of vascu-
litides. The CTD-related disorders such as Sjögren’s syndrome (SS), mixed connective tissue 
disease (MCTD), etc., are also captured under the extended umbrella of CTD, as they share 
similar features. Involvement of the respiratory system occurs in those diseases and may be 
often major contributor to significant morbidity and mortality [5]. The clinical presentation is 
variable, ranging from cough, dyspnea, pleuritic pain to abnormal diffuse lung shadows on 
chest X-ray, in addition to clinical features suggestive of rheumatic disorders, i.e., arthralgia, 
Raynaud’s phenomenon, and skin rashes. Some patients may have presentations dominated by 
pulmonary manifestations over those of autoimmune disease. Thus, it is crucial for physicians 
to carefully evaluate the evidence of underlying CTDs in all patients who present with ILD.
3.1. Prevalence of ILD
ILD, especially IP, is one of the most common and clinically important complications of the 
various CTDs and the CTD-related disorders of which the most often implicated disorders 
Pattern Histology CT features
UIP Subpleural and peripheral fibrosis. Temporal and 
spatial heterogeneity. Scattered fibroblastic foci and 
honeycombing are key features
Basal, subpleural reticulation and honeycombing; 
traction bronchiectasis; little, if any, ground-glass 
attenuation
NSIP Uniform interstitial involvement by variable 
degrees of degrees of fibrosis and inflammation. 
Honeycombing is rare
Bilateral patchy ground-glass opacities admixed 
with reticulation and traction bronchiectasis/
bronchiolectasis. Little or no honeycombing. 
Usually, predominantly basal
OP Connective tissue plugs within small airways and 
air spaces (Masson bodies). In its “pure” form, little 
or no inflammation or fibrosis in the surrounding 
interstitium
Airspace consolidation, with a predominantly 
basal/peripheral or peribronchovascular 
distribution. Bands with air bronchograms and a 
perilobular pattern can also be seen
DIP Extensive macrophage accumulation within the 
distal air spaces. Mild interstitisal involvement
Patchy ground-glass opacities. Microcystic 
change can be seen within the ground-glass, 
Basal, peripheral distribution frequent
LIP Bronchiolocentric lymphoid tissue hyperplasia Ground-glass attenuation is the predominant 
finding, with thin-walled cysts frequently present. 
Lung nodules and septal thickening may also be 
seen
RB-ILD Bronchiolocentric macrophage accumulation. Mild 
bronchiolar fibrosis
Centrilobular nodules, ground glass opacities. 
Diffuse or upper lung distribution
DAD In the acute phase: hyaline membrane, edema. 
In the organizing phase: airspace and interstitial 
organization
Acute phase: diffuse ground-glass opacities and 
consolidation in dependent areas. Organizing 
phase: reticular pattern, traction bronchiectasis 
and architectural distortion
Abbreviation: DIP, desquamative interstitial pneumonia; NSIP, non-specific interstitial pneumonia; UIP, usual 
interstitial pneumonia; OP, organizing pneumonia; DAD, diffuse alveolar damage; RB-ILD, respiratory bronchiolitis 
interstitial lung disease; LIP, lymphocytic interstitial pneumonia.
Adapted from de Lauretis et al. [11].
Table 2. Classification of histological and radiological patterns for IP.
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are SSc, RA, PM/DM, Sjögren’s syndrome (SS), mixed connective tissue disease (MCTD), and 
SLE, according to prevalence [12, 13]. The frequency of ILD in CTDs is presented in Table 3 
[12]. Essentially, as every component of the lungs is a potential target for CTDs, there is a wide 
variety of pulmonary manifestations associated with the diseases [13].
3.2. Multidisciplinary diagnostic approach
Though the prevalence of ILD in CTDs varies based on patient selection and methods used 
for detection, the percentage appears to be higher than previously regarded. ILD may pre-
cede the extrapulmonary manifestations of CTD as a forme fruste of systemic disease, in some 
patients by years, while the rheumatic symptoms predate ILD in others [14–16]. Sometimes, 
it makes the distinction between idiopathic pulmonary fibrosis (IPF) and CTD-related ILD 
difficult [11, 16]. Despite similarities in clinical and pathologic presentation, the prognosis 
and treatment of CTD-associated ILD can differ greatly from that of other forms of ILD such 
as IPF [13, 16, 17]. Therefore, early detection of pulmonary involvement and early accurate 
diagnosis of CTDs are both important for initiating appropriate intervention. The multi-
disciplinary diagnostic team (MDD team), including a pulmonologist, a pathologist, and a 
rheumatologist, can contribute to it; a report indicates that 50% of patients referred with an 
initial concern for IPF had their diagnosis changed to a CTD-ILD after combined evaluation 
by the specialists [12].
The evaluation of ILD in patients with CTD is complex due to the heterogeneity of CTDs, the 
varied types and severity of ILD, and also the fact that ILD may be identified at any point in 
time in these patients. Fischer, et al. emphasize the importance of cross-disciplinary collabo-
ration and thorough evaluations, which are needed either when CTD patients develop ILD 
or when encountering ILD patients with possible occult CTD [18]. The detection of occult 
CTD in patients with “idiopathic” ILD requires careful attention to historical clues, subtle 
physical examination findings, and autoantibody profiles, as well as radiologic and histo-
pathological features. Such evaluation can be optimized by a multidisciplinary approach in 
collaboration with specialists including radiologists, pathologists, and rheumatologists. The 
standard clinical approach for evaluating patients with ILD for CTDs is well summarized by 
Vij R and Strek ME in their review [5].
Connective tissue disease Frequency of ILD Patterns
Systemic sclerosis 45% (clinically significant) NSIP 80–90%, UIP 10–20%, OP, DAD
Rheumatoid arthritis 5–58% UIP 50–60%, NSIP 30–60%, OP, LIP, DAD, DIP
Polymyositis/dermatomyositis 30–70% NSIP, OP, UIP, DAD
Sjögren’s syndrome Up to 25% NSIP, OP, UIP, LIP
Systemic lupus erythematosus 2–8% NSIP, OP, UIP, DAD
Mixed connective tissue disease 20–60% NSIP, OP, UIP, DAD
Modified from Castelino et al. [12].
Table 3. Features of ILD associated with CTD.
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3.3. Laboratory tests and biomarkers
Since the spectrum of ILD associated with CTD is broad, careful evaluation for autoantibod-
ies or other serologic tests in conjunction with clinical features of autoimmune disease is 
crucial [19, 20]. Because of the variable incidence and outcome of ILD in CTD, biomarkers 
including autoantibodies are critical for diagnosis, prognosis, patient subtyping, and pre-
dicting response to treatment. Major autoantibodies and serologic tests commonly available 
for the evaluation of CTD-ILDs include antinuclear antibody (ANA), anti-double-stranded 
DNA, anti-ribonucleoprotein (anti-RNP) antibody, anti-Smith (anti-Sm) antibody, anti-sclero-
derma-70 (Scl-70) antibody, anti-Ro (SS A), anti-La (SS B), anti-Jo-1 antibody, rheumatoid fac-
tor (RF), and anti-cyclic citrullinated peptide antibody (ACPA) [5].
Some of the established biomarkers include lung epithelium-specific proteins [20]. Evidence 
indicates that repetitive injuries to alveolar epithelial cells (AEC) and airway Club cells trigger 
an exaggerated wound healing response. During the process, while AEC type I cells undergo 
apoptosis, regenerated hyperplastic AEC type II cells produce a vast array of cytokines, 
growth factors, and release surfactant proteins and mucins [21]. Surfactant proteins (SP-A 
and SP-D) and KL-6 in the serum are useful biomarkers, which have been well established for 
various ILDs. SP-D and SP-A, secreted by AEC II and airway Club cells, are surfactant lipo-
proteins and phospholipids which stabilize alveolar surface tension, playing an important 
role in the lung host defense system [22]. SP-D serum levels are more sensitive than SP-A in 
detecting ILD as defined by CT but less specific [23]. KL-6 is a high-molecular-weight mucin-
like glycoprotein, now classified as MUC1, which is highly expressed by AEC II and bron-
chiolar epithelial cells and increases following cellular injury and/or regeneration [24]. KL-6 
has profibrotic and antiapoptotic effects on lung fibroblasts [25]. Serum KL-6 has been shown 
to be elevated not only in IIP but also in CTD-ILD, as well as hypersensitivity pneumonitis, 
drug-induced pneumonitis, etc. [24, 26].
There are a number of principal autoantibodies which have been validated for the clinical use.
Antinuclear antibody (ANA) determined by an immunofluorescence assay is most versatile, 
presenting with several major patterns; mainly homogeneous (associated with ANAs against 
double strand (ds) DNA in SLE and histones), speckled/peripheral (less specific), and nuclear 
(most often associated with limited scleroderma). ANA titer higher than 1–160 is regarded as 
significant in most laboratories [27]. When using enzyme immunoassay (EIA) and enzyme-
linked immunosorbent assay (ELISA) for ANAs, we can detect single autoantigens such as 
dsDNA, Smith antigen, scleroderma (Scl-70) (also termed topoisomerase-1), SSA/Ro, SSB/La, 
etc. [27]. Some of the recent, newly developed autoantibodies with distinct clinical and immu-
nological characteristics will be explained later.
3.4. Undifferentiated connective tissue disease (UCTD) and interstitial pneumonia with 
autoimmune features (IPAF)
Besides classical, well-established CTDs, increasing attention has been paid to pulmonary 
involvement in undifferentiated CTD (UCTD) [15, 17, 28–30]. UCTD has been generally 
defined as a condition that presents with signs and symptoms suggestive of CTDs along with 
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positive ANA but does not fulfill any rheumatology classification criteria for specific CTDs 
[30, 31]. Mosca et al. reported that 60% of patients with UCTD remain undifferentiated. When 
evolution to defined CTD occurs, it usually does within the first 5 years of disease. UCTD may 
develop into any of the CTDs, most often into SLE [29]. There are a large number of patients, 
in whom the IP appears to be the lone part for the clinically predominant manifestation of an 
occult CTD with subtle clinical features that suggest an autoimmune process but not meet 
established criteria for CTD, raising a controversy over the strategies for identification and 
classification of these patients. Well-organized prospective studies have been needed to better 
understand this entity of the lung disease and distinguish it from the ILD with well-defined 
CTD or IIP. Proposed terminology to classify such patients includes “undifferentiated CTD” 
[31], “lung-dominant CTD” [15], and “autoimmune-featured ILD” [32]. Recently, the “ATS/
ERS Task Force on Undifferentiated Forms of CTD-associated ILD” created consensus regard-
ing the nomenclature and classification criteria for patients with IIP and features of autoim-
munity and proposed the term “interstitial pneumonia with autoimmune features” (IPAF). 
The classification criteria require evidence of IP and are organized around three central 
domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain 
consisting of specific autoantibodies, and a morphologic domain consisting of specific chest 
imaging, histopathologic, or pulmonary physiologic features [33]. Currently, it is not yet clear 
whether IPAF is a distinct phenotype of ILD or simply a part of IIP. Adopting IPAF classifica-
tion may provide platform for the future study of a more uniform cohort, and prospective 
survey will be needed in determining efficacy of therapy and outcomes for the patients [34].
4. Pulmonary histopathology in connective tissue disease
The underlying pathology in CTD-associated ILD can be dominated by inflammation or 
fibrosis or by a combination of both with distinct radiologic and histopathologic patterns [12]. 
Classification of histological and radiological patterns developed for IIPs is applied to CTD-
ILD [1, 5, 11]. The radiological and corresponding histological patterns defining each entity of 
CTD-associated IP are summarized in Table 2 [11]. Although there is substantial histological 
overlap among the pulmonary manifestations of different CTDs and with other etiologies, 
certain histologic patterns may favor one CTD over another, and occasionally distinctive his-
tologic clues may be present [35, 36]. It is possible in many cases to confirm CTD-ILD and 
guide patient management using histologic features. Pulmonary histopathology is thus help-
ful, and surgical lung biopsy remains the gold standard for evaluation of CTD-associated 
ILD [35]. ILD can present acutely or chronically, with acute presentations being more com-
mon in SLE and PM/DM. Histological patterns of CTD-associated IP include, most frequently, 
nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing 
pneumonia (OP), diffuse alveolar damage (DAD), and lymphocytic interstitial pneumonia 
(LIP). By contrast, desquamative interstitial pneumonia (DIP) and respiratory bronchiolitis-
associated interstitial pneumonia (RB-ILD) are uncommon forms of IP in CTD. Both, typically 
affecting cigarette smokers, share overlapping clinicopathological features and have a rela-
tively better prognosis than UIP.
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4.1. Nonspecific interstitial pneumonia (NSIP)
In the history of classification, the recognition that the cases of ILD exist from which lung 
biopsy samples do not fit into any well-defined histologic patterns of idiopathic IP led to pro-
posals of the terms “unclassified interstitial pneumonia” by Kitaichi in 1990 [37] and “nonspe-
cific interstitial pneumonia/fibrosis (NSIP)” by Katzenstein and Fiorelli in 1994 [38]. This novel 
concept has helped to identify a group of ILDs with a more favorable prognosis and which 
needs to be distinguished from IPF/UIP, while also having different characteristics from DIP, 
AIP, and COP [1]. Katzenstein, in her large study of 64 such cases, utilized the descriptive 
term “nonspecific interstitial pneumonia/fibrosis (NSIP),” which was characterized by vary-
ing proportions of interstitial inflammation and fibrosis that appeared to be occurring over 
a single time span (i.e., a temporally uniform process). NSIP may have varying etiologies, 
including underlying CTD as well as organic dust or other exposures [38]. Subsequent inten-
sive studies in collaboration with pathologists and radiologists have endorsed its differentia-
tion from other types of IP, gaining the term NSIP, a broad acceptance [39, 40]. NSIP pattern 
of lung injury, itself further subdivided into cellular and fibrotic NSIP, is the most common 
pattern of IP in all CTDs except for RA, in which UIP pattern pathology may be more common 
[41, 42]. NSIP lung injury is characterized by diffuse, although often variable, alveolar septal 
thickening due to collagen deposition. The amount of associated interstitial inflammation var-
ies, but in most cases, it consists of mild patchy lymphoplasmacytic infiltrate. Although NSIP 
is not a pattern specific to CTD-IP, there are several histologic clues which support CTD, and 
when found, make the diagnosis of CTD-IP more likely [35].
• Involvement of multiple lung components: concurrent involvement of alveolar septal in-
terstitium, airways, vessels, and pleura is an important clue to the diagnosis of CTD-IP and 
can be helpful in differentiation of it from IPF.
• Interstitial fibrosis with overlapping NSIP and UIP: a histologic overlap of UIP and NSIP 
patterns is frequently shown in CTD, although similar findings may be seen in some vari-
ants of chronic hypersensitivity pneumonia, etc.
• Lymphoid aggregates: formation of prominent lymphoid aggregates, often with germinal 
centers, is a characteristic feature of CTD-IP, classically seen in RA and Sjögren’s syndrome.
4.2. Usual interstitial pneumonia (UIP)
UIP is the prototype of histopathology which characterizes IPF, a chronic form of idiopathic 
interstitial lung disease [1, 2]. UIP pattern is often encountered in CTD-IP, with more preva-
lence in advanced cases. This pattern is classically identified by its patchy nature (spatial het-
erogeneity) and chronic active appearance (temporal heterogeneity). Fibrosis is accentuated in 
the subpleural regions with microscopic honeycombing observed as irregular airspaces sur-
rounded by dense fibrosis. Fibroblast foci (regions of new fibrosis) are found at the interface 
between central and peripheral regions [35]. While primary UIP pattern is found in 13–56% 
of RA-ILD cases, some studies have reported that the most frequent histologic pattern of ILD 
among RA patients is NSIP, followed closely by UIP, accounting for 30–67% and 13–57% of 
RA-ILD, respectively [36]. Studies of PM/DM-ILD identified an UIP pattern in 5–33% of cases. 
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In SSc-ILD, UIP pattern was found in 15% in one study and 26% in another. UIP pattern has 
also been reported in 17% of Sjögren’s syndrome cases in a study. Whereas idiopathic pulmo-
nary fibrosis (IPF) is a progressively deteriorating ILD, in which the characteristic histologi-
cal pattern of IPF is UIP; interestingly, a UIP pattern is associated with a significantly better 
survival in CTD compared to the IPF [43]. Histologically, CTD-associated UIP biopsies had 
fewer fibroblastic foci, smaller honeycombing spaces, higher numbers of germinal centers, 
and higher inflammation scores than IPF/UIP biopsies [44].
4.3. Diffuse alveolar damage (DAD)
Since 1935, when Louis Hamman and Arnold Rich described four patients with acute respi-
ratory failure of unknown etiology, the existence of cases which manifest acute respiratory 
failure with bilateral lung infiltrates has been recognized [45]. All four patients died and were 
revealed at autopsy to have a distinctive pathology that in modern times is recognized as the 
organizing stage of diffuse alveolar damage (DAD). This acute idiopathic respiratory condi-
tion was subsequently given the eponym Hamman-Rich syndrome. Although the histology of 
DAD was described even earlier, the term of “diffuse alveolar damage” (DAD) was presented 
by Katzenstein, et al. in their comprehensive review with their own data [46]. They concluded 
that endothelial and alveolar cell injury leads to fluid and cellular exudation, with hyaline 
membranes and edema being well-known features.
The term “acute interstitial pneumonia” (AIP) was introduced in 1986 by Katzenstein et al. for 
cases identical to the Hamman-Rich syndrome to lay emphasis on the fact that the condition is 
an acute form of idiopathic interstitial lung disease, clinically and histologically distinct from 
chronic forms, the prototype of which is IPF [47]. The prognosis of AIP is dismal and the mor-
tality high. Today, AIP is defined by the following key elements: acute onset of respiratory 
symptoms typically resulting in acute respiratory failure; bilateral lung infiltrates on radio-
graphs; the absence of identifiable etiology; and histological documentation of DAD [1, 47, 
48]. Whereas the term AIP is applied when DAD is of unknown etiology, similar injury due to 
a known cause is generally referred to as DAD (stating the cause or the underlying disease).
DAD is thus a histologic pattern of injury usually associated with a life-threatening acute or 
subacute presentation which often correlates with the clinical entity of acute respiratory dis-
tress syndrome (ARDS) [49]. In earliest phase, the histology of DAD comprises alveolar septal 
edema and fibrin deposition in airspace. Over hours to days, these changes are accompanied 
by fibroplasia in alveolar septa, accumulation of alveolar macrophages (including foam cells), 
and formation of hyaline membranes [50]. Organizing thrombi are often found in small to 
medium-sized arteries. Within days to weeks after injury, airspace plugs of organizing pneu-
monia and type II pneumocytes hyperplasia on alveolar surfaces become prominent, repre-
senting a histologic pattern described as “organizing DAD.”
Besides AIP, infection is the most important etiology to exclude in patients in whom a diagno-
sis of AIP is clinically considered. Infectious etiology includes fungi, pneumocystis organisms, 
and viruses such as cytomegalovirus (CMV), etc. Despite prominent neutrophilia observed in 
bronchoalveolar lavage (BAL) fluid samples, there is usually a paucity of inflammatory cells 
on histologic sections in case of AIP. If prominent acute inflammation is seen, particularly in 
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the airspaces, it raises suspicion of infection. Other clues to specific etiologies include viral 
cytopathic changes observed in some viral pneumonias (e.g., cytomegalovirus, respiratory 
syncytial virus, adenovirus); food or other foreign material (with or without giant cell reac-
tion) suggesting aspiration; and prominent eosinophilia suggesting a primary eosinophilic 
disorder such as eosinophilic granulomatosis with polyangiitis (EGPA/Churg–Strauss syn-
drome) or acute eosinophilic pneumonia [35].
CTDs are another major group of diseases that may manifest pathologically as DAD. To identify 
CTD as an etiology of DAD in patients, exclusion of other possible cause must be established. 
Of note, DAD usually occurs in patients with established CTD-ILD but also can occasionally 
be the presenting manifestation of the disease [51]. In CTD patients who initially present with 
DAD, rheumatologic manifestations and serological tests should help to establish the correct 
diagnosis. In patients with CTD on immunosuppressive therapy, infectious etiology and drug 
toxicity should be considered as a potential cause of DAD. In SLE, cases of diffuse alveolar 
hemorrhage commonly show histological features of DAD [52]. In PM/DM, an older case series 
found DAD pattern in 4 of 15 cases (27%); a more recent series identified DAD in 2 of 70 cases 
(3%), possibly reflecting improvements in diagnosis and treatment of this disease [53, 54]. A 
study suggests that DAD is more common in DM-ILD than in PM-ILD [55]. In RA, one study 
reported primary DAD pattern found in 2 of 33 cases (6%) [56]. In a more recent study of CTD-
associated DAD, RA accounted for five of nine cases; in four cases, DAD occurred in patients 
with established, pre-existing RA-ILD, whereas one manifested as a de novo presentation [51].
4.4. Organizing pneumonia (OP)
While OP is characterized by fibrosis and chronic inflammation like IP, it differs in that the 
reaction affects predominantly the airspaces rather than the interstitium; this disorder is not 
an interstitial process [57]. However, many include OP in the classification of IP [40]. OP is his-
tologically characterized by consolidation of airspaces by rounded branching polypoid plugs 
of granulation tissue [35]. This airspace organization is usually found in the alveoli as well as 
terminal airways. Pure involvement of airways is rare, and thus, it should raise suspicion of a 
primary small airway disease. Alveolar macrophages with foamy cytoplasm are often found; 
however, this nonspecific finding may also be observed in cases of aspiration or drug toxicity. 
Usually, there are not abundant neutrophils in the histology of OP. If prominent inflammation, 
particularly involving the airspaces, is found, it should raise suspicion of infection as a cause. 
Also, when eosinophils are prominent in the airspace, suspicion of a primary eosinophilic disor-
der, e.g., EGPA/Churg-Strauss syndrome, eosinophilic pneumonia, etc., or a drug adverse reac-
tion must be raised. Overall, a predominant OP pattern, if encountered, accounts for a broad 
range of differential diagnosis to be considered, which include CTD, infectious pneumonia 
(particularly viral or atypical bacterial), aspiration, and drug toxicity. Thus, after all diagnostic 
exclusion is made, cryptogenic organizing pneumonia (COP) is determined as the diagnosis.
In many cases of CTD, the associated ILD may demonstrate focal lesions of OP pattern super-
imposed on a background of the other patterns of IP, frequently seen in NSIP. Therefore, 
true OP is less common in CTD-ILD. Among the RA-ILD, one study reported a primary OP 
pattern in 2 of 18 cases of RA-ILD (11%), and another stated 6 of 40 cases (15%) [42, 56]. Of 
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note, OP can occasionally be the inaugural manifestation of RA [58]. In PM/DM-ILD, OP is 
common; OP as the primary pattern was present in 6 of 15 cases (40%) in one series, 5 of 13 
(38%) in another [53, 59]. In a study of cases with Sjögren’s syndrome reported, OP was found 
in 4 of 18 biopsies (22%) in the series [51]. By contrast, OP is a very rare manifestation in SSc; 
detected only in 1 of 80 cases in a large series [60].
4.5. Lymphocytic interstitial pneumonia (LIP)
The term “lymphocytic interstitial pneumonia” (LIP) refers to a pattern of IP in cases with dif-
fuse and marked thickening of alveolar septal interstitium predominantly by dense lympho-
cytic infiltrate [61]. The infiltrate is polyclonal and may be admixed with variable numbers 
of plasma cells and macrophages. Germinal centers are frequently present. Histologically, 
LIP overlaps with follicular bronchiolitis and nodular lymphoid hyperplasia. When present, 
LIP pattern may raise concern for a possible lymphoproliferative process, which should be 
ruled out using appropriate immunohistochemical studies and flow cytometric analyses [35]. 
It should be noted that LIP has been associated with some viral infections, particularly human 
immunodeficiency virus. Classically, LIP was well-recognized in Sjögren’s-associated ILD, 
where it was initially reported in at least 25% of cases based on a series of 12 biopsies [62]. A 
more recent study identified LIP primary pattern in 3 of 18 cases of Sjögren’s-ILD (17%) [51].
5. Characteristic of interstitial lung disease in major connective tissue 
disease
5.1. Interstitial lung disease in systemic sclerosis
SSc is recognized as the CTD with the highest prevalence of ILD, ranging from 40 to 80%, 
depending on the modalities used for ascertainment [63]. The frequency of ILD varies accord-
ing to patient selection, subsets of skin disease extent and ethnicity. In a large autopsy study, 
ILD was the most common pulmonary lesion in SSc, being found in >70% of the cases, and 
arteriolar thickening, described as medial hypertrophy or concentric intimal proliferation, 
was the most specific lesion in the lungs suggestive of pulmonary hypertension, being noted 
in 29% of the patients [64]. SSc, classically “scleroderma,” is defined by the presence of major 
criteria; i.e., skin thickening proximal to metacarpo-phalangeal joints and minor criteria; i.e., 
sclerodactyly, esophageal involvement, and lung fibrosis [65]. It is subdivided into a limited 
cutaneous form, including CREST (Calcinosis, Raynaud’s syndrome, Esophageal dysmotility, 
Sclerodactyly, Telangiectasia) syndrome and a diffuse cutaneous form (diffuse SSc has skin 
sclerosis proximal to elbows and knees), with varying degrees of skin, esophageal, lung, car-
diac, and vascular involvement. Both forms can be progressive in nature.
As mentioned above, pulmonary manifestations in SSc include ILD and vascular disorder 
manifesting as pulmonary arterial hypertension (PAH). Today, both pulmonary complica-
tions are the leading cause of morbidity and mortality in patients with SSc. In line with SSc 
as the vasculature disorder, ranging from Raynaud’ s phenomenon to PAH and renal crisis, 
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nailfold capillary microscopy is now a well-established measure to evaluate capillary dam-
age or abnormality [66]. The capillary changes observed in digits can be a predictor of severe 
vascular complications, being helpful in recognizing early disease [67].
In the context of autoantibodies, anti-nuclear antibodies (ANA) are found in the majority of 
SSc patients although not in every case. In 2013, the novel classification criteria of American 
College of Rheumatology (ACR)/European League against Rheumatism (EULAR) collabora-
tive initiative for SSc incorporated three major autoantibodies [68]. These antibodies with 
high specificity for SSc are against topoisomerase (ATA or anti Scl-70), anticentromere anti-
bodies (ACA), and anti-RNA polymerase III (ARA). They are closely related to distinct disease 
patterns; anti-topoisomerase antibodies are strongly associated with ILD, whereas anticentro-
mere antibodies are highly predictive of the absence of significant lung fibrosis but associated 
with development of pulmonary hypertension [69]. Anticentromere antibodies, which are fre-
quently found among Caucasians (20–35%), are strongly indicative of a limited form disease 
referred as CREST syndrome [69]. The other major autoantibody, anti-RNA polymerase III, is 
linked to diffuse skin disease and renal crisis, with less significant lung fibrosis. This antibody 
has another aspect that may herald paraneoplastic SSc [70]. While almost all patients with 
anti-topoisomerase antibodies have some extent of ILD, more than half of the SSc patients 
with ILD are negative for this antibody.
The most common pattern of ILD in SSc is fibrotic NSIP which manifests as dense, paucicel-
lular interstitial fibrosis that maintains the underlying architecture [60, 71, 72]. As the lung 
disease progresses, the areas of fibrosis may become confluent and appear as honeycomb. SSc 
patients may also present with typical UIP pattern with temporal and special heterogeneity, in 
contrast to the diffuse and uniform fibrosis of NSIP. In most SSc patients, ILD remains stable 
without treatment despite having some degree of lung fibrosis. However, some proportions 
of the SSc patients develop significant and progressive ILD. In SSc-associated ILD, placebo-
controlled randomized trials, named the Scleroderma Lung Study (SLS) and the fibrosing 
alveolitis scleroderma trial (FAST), have been performed, suggesting certain effectiveness of 
immunosuppressive therapy in preventing further decline in patients with progressive ILD 
to be mentioned later [73, 74].
5.2. Interstitial lung disease in rheumatoid arthritis
RA is the most common CTD, occurring in 1–2% of the population, more frequently in 
women. Although RA is primarily characterized by synovial inflammation which leads an 
erosive inflammatory polyarthropathy, predominantly affecting the distal joints, extra-artic-
ular manifestations are seen in approximately half of patients with RA. Extra-articular mani-
festations include subcutaneous nodules, skin ulceration, scleritis/episcleritis, pericarditis, 
splenomegaly, and a variety of pleuro-pulmonary abnormalities.
Lung disease accounts for 10–20% of mortality in RA, second only to cardiac disease [75–77]. 
Airway, pleural, vascular, and parenchymal involvement can occur in RA patients, as well as 
pulmonary disorders indirectly associated with RA such as opportunistic infections and drug-
induced lung disease. All pleuro-pulmonary manifestations in RA are more common in males; 
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ILD affects men twice as commonly as women. The prevalence of ILD ranges widely from 5 to 
58% in various reports [78–80]. It is difficult to confirm the exact prevalence because it depends 
on modalities of ascertainment and patient selection such as autopsy, hospital, and commu-
nity-based studies. In a study of 36 patients with new onset RA, abnormalities consistent with 
ILD were found in 58% of patients; physiology 22%, chest X ray 6%, HRCT 33%, BAL 52%, and 
99mTc-DTPA radionuclide scan 15% [81]. Smoking is a significant risk factor for ILD; an odds 
ratio of 3.8 for ILD was observed in RA patients with a smoking history >25 pack years [82].
In the context of histological patterns, the predominant ILD histology in RA patients is NSIP 
(cellular or, more commonly, fibrotic NSIP), followed closely by UIP, accounting for 30–67% and 
13–57% of RA-associated ILD, respectively [42, 44, 59, 83–85]. Some studies have noted greater 
incidence of UIP histology in RA-ILD found in up to 56% of patients in a series [42]. These NSIP 
and UIP patterns are followed by organizing pneumonia (OP). There is evidence suggesting 
that a UIP pattern may be associated with a worse survival than fibrotic NSIP in cases of RA, in 
contrast with the other CTDs. A pattern of DAD/acute interstitial pneumonia (AIP) is infrequent 
but may occur as fulminant ILD manifestation of RA, which can develop in a previously normal 
lung or as the presenting pattern of a previously undiagnosed ILD. The characteristic CT pat-
tern of DAD includes widespread ground glass with/without areas of dependent consolidation, 
although a similar pattern could represent opportunistic or viral infection and acute heart failure.
5.3. Interstitial lung disease in polymyositis/dermatomyositis
Idiopathic inflammatory myopathy (IIM), a group of systemic autoimmune disorders that 
affect skeletal muscles and other organs, comprises three major categories: polymyositis (PM), 
dermatomyositis (DM), and inclusion body myositis (IBM). PM and DM are sometimes recog-
nized together as they share similar clinical signs and symptoms with exception of cutaneous 
manifestations such as “heliotrope rash” on the upper eyelids, “mechanic’s hands” on the 
fingers, and “Gottron papules” on the dorsal surface of the hands seen in DM. Pathologically, 
however, these are distinct entities; PM is T cell-mediated diseases, where CD8-positive cyto-
toxic T cells invade muscle fibers expressing MHC class I antigens, whereas DM is character-
ized by a complement-mediated microangiopathy [86–88].
The diagnosis of PM/DM is made on the basis of clinical features and examinations, which 
include symmetrical proximal muscle weakness, elevated serum muscle enzymes, charac-
teristic electromyographic alterations, muscle biopsy histopathology consistent with myo-
sitis, and for DM, typical cutaneous manifestations mentioned above and less-specific skin 
rashes. Moreover, muscle magnetic resonance imaging (MRI) and ultrasound (US) have 
been also introduced in the diagnostic work up of patients with inflammatory myopa-
thies. Classification criteria for PM/DM date back to initial publications by Medsger et al. 
[89]. Since, in 1975, Bohan and Peter classified myositis, their criteria have been widely used 
[90, 91]. However, it demonstrated poor specificity and cannot distinguish PM from IBM or 
some forms of dystrophies for instance. Thus, several diagnostic criteria for inflammatory 
myopathies have been proposed with little acceptance, including recent muscle-biopsy-based 
diagnostic criteria [92]. Further prospective studies are required to develop improved and 
universal classification criteria.
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Several neuromuscular diseases which may mimic PM/DM and should be considered in 
the differential diagnosis include drug or toxic myopathies (alcohol, colchicine, statins, 
etc.), endocrine myopathies (hyper-hypothyroidism), metabolic myopathies, mitochon-
drial myopathies, muscular dystrophies, infectious myositis, neuropathies, paraneoplastic 
syndromes, other connective tissue disorders, amyloidosis, and sarcoidosis [93]. Muscular 
dystrophies, where an increase of creatine kinase (CK), electrodiagnostic, and bioptic 
abnormalities similar to PM/DM may be present, can be distinguished from DM/PM by 
the positive family history, the relatively early insidious onset, and slow progression. 
Iatrogenic myopathy is secondary to corticosteroids use, where CK is normal and the his-
tological examination shows atrophic changes of muscle fibers. Other diseases to consider 
in the differential diagnosis are endocrine or dysionemia-induced myopathies. Rheumatic 
polymyalgia (polymyalgia rheumatica) is characterized by normal CK and histological 
absence of inflammatory abnormalities. Infectious myositis especially viral and parasitic 
myositis are characterized by a diffuse muscular involvement and a subacute or chronic 
course. Bacterial myositis is localized and acute. Among other rare inflammatory myopa-
thies, nodular focal myositis is considered as a variant of PM/DM and may present at onset 
(As localized, a differential diagnosis with muscular cancers and/or thrombophlebitis must 
be considered). Eosinophilic myositis, characterized by muscle eosinophil infiltrate, may 
be part of a hypereosinophilic syndrome (pneumonia, endocardial and myocardial fibrosis, 
and peripheral neuropathy, etc.) or be associated with eosinophilic fasciitis. Granulomatous 
myositis can be isolated or in the context of granulomatous syndromes, such as sarcoidosis 
or Crohn’s disease; the main histological finding is the presence of granulomatous lesions 
which may contain epithelioid cells, histiocyte, and Langerhans giant cells. In the differ-
ential diagnoses of IBM, polyneuropathy and amyotrophic lateral sclerosis have also to be 
considered [93, 94].
Concerning extra-muscular involvement, respiratory disease is a major cause of mor-
bidity and mortality in PM/DM [53, 95–100]. PM/DM-associated pulmonary disorders 
may manifest as ILD and as a consequence of respiratory muscle weakness leading to 
hypoventilation or aspiration pneumonia. ILD is the most common extra-muscular com-
plication in PM/DM and have been recognized in 30–70% of the patients [100–102]. The 
reported prevalence varies depending on the modalities or tests for detection and patient 
selections. Since Tazelaar et al. reported a histopathological study of lung biopsy speci-
mens in patients with PM/DM in terms of treatment responses and survivals, histopathol-
ogy fairly serves relevant clinical decisions [53]. As for the prevalence of the different 
histopathologic patterns, NSIP is by far the most frequent finding, followed by DAD, UIP, 
and OP [54, 103–107]. Our study with HRCT scans of 14 cases of histologically proven 
NSIP associated with PM/DM showed that the predominant features were of reticular 
and/or ground-glass opacities with or without consolidation. Reticular and ground-glass 
opacities predominated in the lower zone of each lung, and consolidation predominated 
at the lung periphery [108].
In the context of subtypes of PM/DM, the following concepts of amyopathic dermatomyositis 
and anti-synthetase syndrome warrant particular attentions.
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5.4. Amyopathic dermatomyositis
Clinically amyopathic dermatomyositis (CADM), which is characterized by the cutaneous 
findings of DM with no muscle involvement or only minimal weakness, affects approxi-
mately 20% of patients with DM [109, 110]. Patients with CADM have a greater risk of devel-
oping ILD, especially prone to rapidly progressive lung disease corresponding to DAD [111, 
112]. Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (also referred to as 
anti-CADM-140 antibodies) were identified in the serum from patients with CADM by firstly 
immunoprecipitation assays [113]. The presence of anti-MDA5 antibodies is strongly associ-
ated with DM, especially with CADM, and rapidly progressive ILD, which are thus associ-
ated with particularly poor clinical outcomes.
5.5. Anti-synthetase syndrome (ASS)
A subset of patients may manifest a clinical syndrome known as “anti-synthetase syndrome 
(ASS),” which is characterized by the presence of one of the anti-aminoacyl-t-RNA synthe-
tase (ARS) antibodies such as anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, and anti-KS, 
together with stigmata of PM/DM including myositis, ILD, polyarthritis, fever, Raynaud’s 
phenomenon, and mechanic’s hand [114, 115]. Anti-Jo-1, the first anti-ARS antibody, is the 
best understood of the anti-synthetase antibodies, with a strong correlation with ILD in 
patients with PM/DM; the incidence of ILD approaches 90% [116, 117].
5.6. Myositis-specific autoantibodies and myositis-associated autoantibodies
Circulating autoantibodies directed against nuclear or cellular components are frequently 
detected in patients with PM or DM. These antibodies are categorized into two groups; one 
is specific to PM/DM, whereas the other is found in overlap syndrome with myositis. Targoff 
et al. designated these two categories of autoantibodies as “myositis-specific antibodies; 
MSAs” and “myositis-associated antibodies; MAAs,” respectively [114]. Classical autoanti-
bodies such as anti-aminoacyl transfer RNA synthetases (ARS) antibodies, anti-signal recog-
nition particle (SRP) antibodies [118, 119], and Mi-2 antibodies are classified as MSAs, where 
especially anti-Mi-2 antibodies are DM specific [120]. Later, the new DM specific antibodies 
have been disclosed. These include the antibodies directed against melanoma differentiation–
associated gene5 (MDA5) (anti-CADM-140 antibody, mentioned above) [113, 121, 122], tran-
scriptional intermediary factor-1-gamma (anti-p155 antibody) [123, 124], NXP-2 (anti-NMP-2 
antibody) [125, 126], and small ubiquitin-like modifier activating enzyme (anti-SAE antibody) 
[127]. Usually, MSAs are distinct, and their presence is mutually exclusive.
Because of their strong associations with a pattern of clinical features, such as myopathy, skin 
lesions, and ILD, these novel autoantibodies are useful biomarkers for classifying disease sub-
groups, predicting future organ involvement, and forecasting the prognosis of patients with 
PM/DM [114, 128–131]. The autoantibodies are detectable in PM/DM; both MSA and MAA 
are listed and summarized in Table 4 [102]. The pathogenetic mechanisms of expression of 
such autoantibodies are still awaited to be illuminated.
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Autoantibodies Antibody target Frequency in 
polymyositis/ADM/
JDM %
Frequency of ILD 
in adult /juvenile 
myositis %
Clinical spectrum
In adulthood In childhood
Myositis- specific autoantibodies (MSA)
Anti-t-RNA synthetase 29/20/5
Anti-Jo1 (PL1) Histidyl-ARS 21/11/<3 66/63 Arthralgia, fever, RP, 
mechanic’s hand, puffy 
finger
Arthralgia, fever, RP, 
mechanic’s hand, 
sclerodactylyAnti- PL7 Threonyl-ARS 5/2/<1 84/63






Anti-YRS(Ha) Tyrosyl-ARS <1 <1
Anti-Zo Phenylalanyl-ARS <1
Dermatomyositis Specific autoantibodies
Anti-Mi2 Nucleosome remodeling deacetylase 
complex
1/9/4–10 4/0 Classical DM without 
extramuscular involvement
Mild or moderate JDM
Anti-NXP2(MJ,p140) Nuclear matrix protein 2 10/0–3/12–25 0/25 DM without extramuscular 
involvement, calcinosis




gene encoding RNA helicase
<1/14–46/7 Europe:60; Asia:90/
Europe:19; Asia:53
Amyopathic DM, severe 
cutaneous ulcers, rapidly 
progressive ILD
Severe cutaneous ulcers, 
RP-ILP, mediastinal 
emphysema
Anti-TIF1γ(p1555/140) Transcriptional intermediary factor 1γ <1/10–30/14–29 <10/3 Cancer associated DM in 
78% of cases
Mild or moderate JDM
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Autoantibodies Antibody target Frequency in 
polymyositis/ADM/
JDM %
Frequency of ILD 
in adult /juvenile 
myositis %
Clinical spectrum
In adulthood In childhood
Other MSA
Anti-SRP Signal recognition particle 5/1/<3 15/0 Necrotising myopathy Severe JPM
Anti-HMGR(200-100) 3-hydroxy-3-methylglu taryl-
coenzyme A reductase
10/<1/unknown Unknown Necrotising myopathy Unknown




Anti-RO/SSA RNP complexes with small 
cytoplasmic RNAs(hy-RNA)
12/13/0
Anti-U1RNP 70 KDa,A and C polypeptides of U1 
snRNP
5/6/6 7 DM, fever, RP, sclerodactyly
Anti-PM/Scl(75 and 
100 Kda)
PM/Scl complex encompassing 
C1D,PM-SCl-100 and PM-SCl-75 
proteins of the human exosome
6/9/4 38 Fever, RP, sclerodactyly
Anti-Ku 80 and 70 KDa DNA binding dimeric 
protein
2/1/0 27 Fever, RP, sclerodactyly
ADM: adult dermatomyositis; JDM: juvenile dermatomyositis; ILD: interstitial lung disease; SRP: signal recognition particle; ARS: aminoacyl-t-RNA synthetase; RP: 
Raynaud’s phenomenon; DM: dermatomyositis specific rash; RP-ILP: rapidly progressive ILD; JPM: juvenile poly myositis
Adapted from Lega et al. [120].










6. Pathogenesis of interstitial pneumonia associated with connective 
tissue disease
6.1. Classic mechanisms in the pathogenesis of interstitial pneumonia in connective tissue 
disease
Numbers of studies on the pathogenesis of IP have been performed in SSc as well as in mouse 
models of IP, providing evidence for plausible mechanisms that may lead to pulmonary fibro-
sis in CTD. This is natural because, among the whole CTDs, SSc has the highest prevalence of 
IP, and currently, the lung disease consists the major cause of death in patients with SSc, being 
shifted away from mortality due to renal crisis which was more common in the past. The high 
morbidity and mortality due to IP in SSc have been eliciting not only multidisciplinary clini-
cal studies but also basic researches. Many lines of evidence acquired from the studies on SSc, 
and relevant researches on fibrosis have been implying the following potential scenario of 
classic mechanisms in the pathogenesis of CTD-IP [12, 132, 133].
6.1.1. Mediators eliciting and perpetuating interstitial pneumonia in systemic sclerosis
The key mechanisms in CTD-IP involve an interplay between various cell types and humoral 
factors; the pathogenesis is initiated by microvascular injury, leading to endothelial cell dam-
age and alveolar epithelial injury [12, 132, 133]. This is followed by activation of the coag-
ulation cascade, release of various cytokines, e.g., IL-1, IL-4, IL-6, IL-13, chemokines, and 
lysophosphatidic acid (LPA), and growth factors including transforming growth factor beta 
(TGF-β), connective tissue growth factor (CTGF), and insulin-like growth factor (IGF-1), 
which leads to activation of fibroblasts, resulting in the development of fibrosis [12, 132, 134]. 
Many epithelial-derived factors influence the behavior of fibroblasts, with soluble mediators 
known to exhibit profibrotic activities [134]. The pivotal mediator of fibrosis is the multi-
functional cytokine, TGF-β, which, along with platelet-derived growth factor, endothelin-1 
(ET-1), plays a major role in the pathogenesis of SSc. There is evidence that epithelial-to-
mesenchymal transdifferentiation (EMT) occurs in lung fibrosis, and this process is mediated 
by TGF-β and potentially ET-1 [135, 136]. TGF-β responses are mediated by canonical Smad 
signaling [137]. Binding of TGF-β to its receptor elicits signaling through phosphorylation 
and nuclear translocation of cytoplasmic Smad protein, triggering transcription of genes such 
as type I collagen, fibronectin, α-smooth muscle actin, and CTGF, which promote fibrogen-
esis [138]. ET-1 is a potent vasoconstrictor produced by endothelial cells, epithelial cells, and 
mesenchymal cells. ET-1 binds to ET-1A and ET-1B receptors, recruits fibroblasts, stimulates 
extracellular matrix production, and also stimulates TGF-β production in lung fibroblasts 
[139]. Elevated levels of ET-1 have been found in the blood vessels, lung, kidneys, and skin 
of SSc patients [140]. LPA is produced by activated platelets and fibroblasts. The LPA recep-
tor is expressed in fibroblasts, endothelial cells, and epithelial cells. Both are involved in the 
development of lung fibrosis in mouse model of IPF, suggesting LPA mediates fibroblast 
recruitment [141]. IGFs have been implicated in pulmonary fibrosis because increased levels 
of IGF-1 are detected in the serum as well as in the BAL of SSc patients [142]. CTGF, also 
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known as CCN2, which plays a pivotal role in the stimulation of extracellular matrix produc-
tion and myofibroblast differentiation, is involved in angiogenesis and forming the connec-
tive tissue [143]. The levels are elevated in the skin and lungs from SSc patients as well as in 
the sera [144].
The earliest events of the parenchymal lung involvement in CTD include inflammation and 
associated alveolar epithelial injury which occurs due to undetermined causes or can be 
caused by some environmental pathogens. The alveolar epithelial damage and inflamma-
tion let resident fibroblasts of pulmonary interstitium to locate to the alveolar wall, and the 
fibroblasts become activated through a variety of mediators such as TGF-β [145, 146]. The 
activation of resident fibroblasts was shown to be induced by the recruitment of active TGF-β 
from the lung tissue [147]. The resident lung fibroblasts play a pivotal role in lung fibrosis, 
and they are considered to be a more primitive or less differentiated lineage of fibroblasts 
that are prepared for repair at injury response [148]. The recruitment of activated fibroblasts 
and myofibroblasts that produce large amount of extracellular matrix proteins occurs in 
the process. These population of cells are not only derived from resident interstitial fibro-
blasts but also come from circulating progenitor cells which include mesenchymal stem cells 
recruited from the bone marrow and cells of a monocyte lineage that localize to the lung [149]. 
Myofibroblasts persist as critical profibrotic cells in affected lung tissue. It is conceivable that 
minor injury and subsequent disease process lead to the development of a lung microenvi-
ronment prone to fibrosis. That series of events results in an accumulation of constituents of 
the extracellular matrix (ECM), which remodels normal tissue architecture, which in turn 
culminates in pulmonary organ failure. Essentially, the lung is primed to develop fibrosis 
in response to injury, and it is likely that the intrinsic response is more severe in CTDs than 
normal individuals. Thus, in SSc, such genetic or intrinsic differences can be reflected to the 
serological phenotypes such as the expression of autoantibodies. Patients with SSc having 
anti-topoisomerase antibodies are liable to develop significant lung fibrosis, while those with 
anti-RNA polymerase III antibodies are less [150].
6.1.2. Involvement of immune mechanisms in interstitial pneumonia in systemic sclerosis
The immune system is also implicated in the pathology of SSc. Several lines of evidence sug-
gest that a specific population of activated T cells exhibiting type 2 helper T (Th2) phenotype 
potentially mediates tissue fibrosis, secreting IL-4 and IL-13 both of which activate fibroblasts 
and collagen production by inducing TGF-β [151]. In SSc, T cells with memory phenotype 
were found in lung biopsy specimens from patients with lung involvement [152]. In some 
studies reported, increased numbers of lung memory CD8 T cells are associated with more 
severe pulmonary fibrosis [153–155]. Luzina et al. have shown an increase in CD8 T cells in 
the lungs of SSc patients by using T cells isolated from BAL fluid and demonstrated that a 
subset of patients at higher risk of progressive lung disease had activated, long-lived CD8 T 
cells which could promote fibrosis through production of profibrotic factors such as IL-4 and 
oncostatin M, as well as activation of TGF-β [156]. Regulatory T cells (Tregs) which maintain 
self tolerance can be impaired in their ability to suppress CD 4 effector T cells [157]. Currently, 
the precise knowledge of the role of effector cells in innate and adaptive immune system in 
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SSc-associated IP is rather insufficient. More fundamental investigations in this aspect are 
needed to address to many queries as to the whole scenario of the development of IP in CTDs.
Besides, as concerns idiopathic pulmonary fibrosis (IPF), the latest evidence of immune 
mechanisms in IPF was reviewed in the recent literature, which includes involvement of both 
innate immunity and adaptive immunity at several levels of the processes toward develop-
ment of fibrinogenesis in the human lung of IPF or in its model mice, as summarized in 
Table 5 [158]. Briefly, in adaptive immune system, the role of T cells seems complex and 
subset dependent; Th2 and Th17 cells were shown to promote pulmonary fibrosis, although 
Th1, Th22, and γδ-T cells have been found to attenuate fibrotic disease. Treg and Th9 sub-
sets have been proposed to exert both anti- and profibrotic effects. In innate immunity, M2 
macrophages and neutrophils have been suggested to enhance pulmonary fibrosis, whereas 
M1 macrophages were assigned a protective role, but contradictory findings have also been 
described [158].
After all, a variety of studies on the pathogenesis of IPF have been conducted, and many 
experimental models were generated to explore the mechanisms. However, it is yet highly 
questionable whether the evidence provided from the studies of IPF is applicable to the eti-
ology of CTD-associated IP. Furthermore, it is still unclear whether the animal models such 
as the mouse bleomycin model can truly replicate the autoimmune progressive forms of the 
ILDs seen in human CTDs.
6.2. A new insight into the pathogenesis of interstitial pneumonia in connective tissue 
disease: “T cells trigger interstitial pneumonia in polymyositis/dermatomyositis”
We have speculated that exploring the early immune phases of IP in the lung would be the 
most direct approach to understand the pathogensis before more complex secondary immune 
responses occur in the evolution of IP [6, 7]. PM/DM is one of the major CTD, of which the 
most critical problem is pulmonary involvement. As mentioned before, ILD, mainly IP, often 
severe and progressive, has been recognized in 30–70% of PM/DM patients and is frequently 
associated with a dismal prognosis. While the presence of myositis-specific autoantibodies, 
such as Jo-1 and activated T cell muscle infiltrates, suggests autoimmune mechanisms in the 
etiology of PM, the pathogenesis of the associated IP remains undefined. We encountered 
two cases of early-stage PM-associated IP, of which we had an opportunity of investigating 
the fresh lung tissues obtained by video-assisted thoracoscopic (VATS) biopsy performed for 
the sake of histopathological diagnosis toward treatment options. Since this is the clear and 
robust demonstration of the pivotal role of T cells in CTD-IP, we herein present the details of 
our study with two cases of early-stage PM-associated IP both suggesting that T cells contrib-
ute to the early phase of the development of IP. Lung tissue was utilized with the approval of 
the institutional review board.
6.2.1. Analysis in cases of interstitial pneumonia associated with polymyositis/dermatomyositis
Patient A was a 51-year-old woman with no tobacco history and no family history of lung 
diseases, referred to our clinic for evaluation of arthralgia and myalgia. At 49 years, the patient 
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noticed Raynaud’s phenomenon and polyarthralgia, for which she was given low-dose pred-
nisolone with clinical improvement. Two months before the referral, she developed polyar-
thralgia and myalgia. On physical examination, the patient had no skin lesions but presented 





T cells Th1 cytokines (IFN-Y and IL-12) attenuate PF, Th2 cytokines (IL-4, IL-5 and IL-13) enhance PF, 
Th17 cells enhance PF, Tregs and Th9 (IL-9) have both pro- and antifibrotic roles in PF; Th22 (IL-22) 
and Yδ-T cells have an antifibrotic role in PF.
Macrophages M1 marcrophages induce myofibroblast apoptosis and digest ECM by activation of MMPs. M2 
macrophages recruit and activate fibroblast through TGF-β1 and PDGF secretion. M2 macrophages 
further produce TIMPs and inhibit degradation of ECM. Both Macrophages phenotypes (M1/M2) 
can exert pro- and antifibrotic effects.
Neutrophils Neutrophils produce elastase, MMPs, and TIMPs. Neutrophil elastase activates TGF-β and recruits 
inflammatory cells to the lung, thereby promoting PF.
Fibrocytes Fibrocytes produce ECM, cross-linking enzymes, chemokines, growth factors, and MMPs, and 
promote PF. Fibrocytes secrete paracrine mediators, which activate resident fibroblasts to promote 
PF. Fibroblasts can differentiate into fibroblasts and myofibroblasts.
Cytokines
IL-1β Profibrotic effects of IL-1β, mediated through IL-1R/MyD88 signaling pathway.
IL-13 IL-13 differentiates human lung fibroblast to myofibroblast through a JNK-dependent pathway.
IL-17 IL-17 interacts/cooperates with TGF-β signaling to promote PF.
TGF-β1 TGF-β promote EMT through SMAD-2/3 signaling pathways. TGF-β1 induces PF through ERK, 
MAPK, PI3K/Akt, and Rho-like GTPase pathways. TGF-β1 differentiates fibroblasts into and 
increase ECM accumulation.
PDGF PDGF stimulates fibroblasts and increase ECM gene expression in fibroblasts.
Chemokines
CCL2 CCL2 increase fibrocyte recruitment and differentiation into fibroblasts, resulting in excessive 
collagen deposition. CCL2 activates M2 macrophage activation and promote PF.
CCL17 CCL17 promotes PF through the recruitment of CCR4^+ Th2 cells and alveolar macrophages.
CCL18 CCL18 increase collagen production in lung fibroblasts through ERK1/2, PKCα, and Sp1/Smad3 
signaling pathways.
CXCL 12 CXCL 12 recruits fibrocytes and activates the Rac1/ERK and JNK signaling pathways to induce 
AP-1 activation and CTGF expression in fibroblasts
Definition of abbreviations: Ap-1, activator protein 1; CCL, CC chemokine; CTGF, connective tissue growth factor; 
CXCL, CXC chemokine ligand; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; ERK, extracellular 
signal-regulated kinase; IL-1R1, IL-1 receptor 1; JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein 
kinase; MMP, matrix metalloproteinase; MyD88, myeloid differentiation primary response gene 88; PDGF, platelet-
derived growth factor; PF, pulmonary fibrosis; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; Rac 1, Ras-
related C3 botulinum toxin substrate 1; SMAD, SMA/MAD homology; Sp1, specificity protein 1; TGF, transforming 
growth factor; TIMP, tissue inhibitors of metalloproteinase; Tregs regulatory T cells.
Adapted from Kolahian et al. [158].
Table 5. Possible immune mechanisms for pulmonary fibrosis.
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rate (ESR) was 135 mm/hr, and C-reactive protein (CRP) level was 1.2 mg/dL (reference range: 
0.0–0.4). Rheumatoid factors (RFs), speckled anti-nuclear factors (ANFs), and anti-histidyl-
t-RNA synthetase (Jo-1) antibodies were positive, while anti-ribonucleoprotein (RNP) and 
anti-scleroderma-70 (scl-70) antibody assays were negative. Levels of lactate dehydrogenase 
(LDH, 798 IU/L) (reference range: 109–435), creatine kinase (CK, 559 IU/L) (reference range: 
44–140), and myoglobin (120 ng/mL) (reference range: 28–60) were elevated. Muscle strength 
was nearly normal, but electromyogram showed myogenic patterns in the muscle groups of 
the upper limb girdle bilaterally. Muscle biopsy revealed lymphocyte infiltration into myofi-
brils and muscle atrophy, consistent with PM. Arterial blood gas analysis demonstrated a pH 
of 7.413; partial pressure of carbon dioxide (PCO
2
), 44.6 Torr; partial pressure of oxygen (PO
2
), 
84.3 Torr; and bicarbonate (HCO
3
-) concentration, 28.4 mmol/L. Pulmonary function tests 
revealed a restrictive pattern; vital capacity (VC) was 74.8%, and diffusing capacity (DLco) 
was 13.44 mL/min/mmHg (67.3%). Analysis of bronchoalveolar lavage fluid (BAL) showed 
75% macrophages, 15% neutrophils, and 10% lymphocytes. Human leukocyte antigen (HLA) 
serotypes were as follows: A2, A26, B15, Cw1, Cw9, DR14, DR8, DR52, DQ7, and DQ6. Chest 
radiography and chest computed tomography (CT) revealed mild, subpleural, linear, and 
reticular opacities in posterior and lateral areas of both lungs (Figure 2a). The patient under-
went video-assisted thoracoscopic (VATS) lung biopsy for histopathologic diagnosis and 
therapeutic planning. Biopsy specimens from anterior basal segment (S8) and lateral basal 
segment (S9) of the right lower lobe revealed an early usual IP (UIP) pattern, demonstrat-
ing heterogeneous lesions with residual air spaces and early fibrotic changes, surrounded by 
mild alveolitis with mononuclear cell infiltrations. Based on these clinical and histopathologic 
findings, the patient was diagnosed with interstitial pneumonia associated with PM. She was 
subsequently treated with methylprednisolone pulse therapy (1 g/day for 3 days) followed 
by oral prednisolone (30 mg/day). Over 10 months, the dose of prednisolone was tapered to 
12.5 mg/day with excellent control of progression of pulmonary lesions and myositis.
Patient B was a 43-year-old woman, a lifetime nonsmoker, referred to our clinic for arthralgia 
and myalgia. The patient had developed Raynaud’s phenomenon 6 months prior to this pre-
sentation. On physical examination, she had swollen fingers, with no skin rash. Fine crack-
les were heard on inspiration in the lower lung fields. No muscle weakness was apparent, 
but thorough examination revealed myositis. Laboratory data were as follows: LDH level, 
616 IU/L; CK level, 410 IU/L; and CRP level, 0.4 mg/dL. Histological examination of mus-
cle biopsy specimen showed mononuclear cell infiltrates in muscle tissue, consistent with 
PM. Assays for RF, anti-dsDNA antibodies, anti-Jo-1 antibodies, anti-centromere antibodies, 
and anti-scl-70 antibodies were negative. ANF (speckled pattern) and anti-ribonucleoprotein 
(RNP) antibodies were positive. Arterial blood gas analysis was unremarkable. Pulmonary 
function testing showed a restrictive pattern; VC, 70.6%, and DLco, 14.71 mL/min/mmHg 
(77.2%). BAL analysis demonstrated 67% macrophages, 11% neutrophils, and 22% lym-
phocytes. HLA serotypes were as follows: A24, A26, B15, B61, Cw10, DR9, DR53, and DQ9. 
Chest radiography and CT revealed subpleural and basilar linear and reticular opacities with 
ground glass attenuation (Figure 2b). Histopathological examination of lung specimens from 
VATS biopsy of superior (S4) and anterior basal (S8) segments of the left lower lobe disclosed 
a nonspecific IP (NSIP) pattern. Specimens showed mild and homogeneous changes with 
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partial inflammatory thickenings of the alveolar wall, with granulation tissues in alveolar 
spaces, fibrosis, and inflammatory-cell infiltrations. Clinical and histopathologic findings lead 
to a diagnosis of IP associated with PM. She was subsequently given pulse therapy with meth-
ylprednisolone (1 g/day for 3 days) followed by oral prednisolone (50 mg/day), which was 
effective in ceasing active myositis and IP. When the dose of prednisolone had been tapered 
to 30 mg/day after 4 months, respiratory function testing showed that %VC and DLco had 
improved to 79.0% and 17.56 mL/min/mmHg (90.7%), respectively.
Immunohistochemical analysis was performed on lung-infiltrating cells utilizing biopsy 
specimens. Substantial infiltrations of mononuclear cells were noted in both patient A (UIP 
pattern) and patient B (NSIP pattern). The mononuclear cells were predominantly CD3+ T 
cells, accompanied by a subtle infiltration of B cells (CD20+), and a minimal number of mono-
cytes (CD19+). Of infiltrating T cells, CD4+ cells were predominant compared to CD8+ cells 
in both cases. We then analyzed T cell receptor α-chain variable region (TCR Vα) and TCR 
β-chain variable region (TCR Vβ) repertoires of T cells infiltrating the lung tissues using an 
adaptor ligation polymerase chain reaction (PCR)-based microplate hybridization assay [159]. 
Quantitative assay has been used in many previous studies, and accuracy and reproducibil-
ity of this assay have been validated [160, 161]. Briefly, total RNA was extracted with TRIzol 
Figure 2. (a) Chest radiography, CT, and photomicrograph of patient A. Chest X-ray and HRCT of patient A show 
subpleural mild linear and reticular opacities in posterolateral lung. Lung biopsy from patient A depicts heterogeneous 
lesions including residual air spaces and early fibrotic changes with fibroblastic foci, mild alveolitis with thickened 
alveolar walls, and mononuclear cell infiltrations (hematoxylin and eosin stain, original magnification ×200). (b). Chest 
radiography, CT, and photomicrograph of patient B. Chest X-ray and HRCT of patient B show thickened interlobular 
septa with bibasilar and subpleural ground glass opacities. Lung biopsy from patient B depicts mild, homogeneous 
changes with partial inflammatory thickening of the alveolar wall, with granulation tissues in alveolar spaces, fibrosis, 
and inflammatory cell infiltrates (hematoxylin and eosin stain, original magnification ×200).
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Reagent (Invitrogen, USA) from lung tissues obtained by VATS biopsy. Complementary DNA 
(cDNA) was synthesized with reverse transcriptase (Superscript II) and BSL-18E primer adap-
tor. Universal adaptor primers were ligated to the cDNA, and PCR was performed with the 
universal primer and primers specific for TCR Cα or Cβ chains. PCR products were biotinyl-
ated by amplification with 5′-biotin primer and the universal primer. The biotinylated PCR 
products were hybridized on microplate wells immobilized with various oligo probes specific 
for TCR Vα or Vβ region sequences. Finally, the amount of biotinylated product bound to 
each probe was measured by quantitative enzyme-linked immunosorbent assay (ELISA) with 
alkaline phosphatase streptavidin. The results of quantitative analysis of TCR Vα or TCR Vβ 
usage in patient A and B are shown in Figure 3a and b, respectively. The open column and 
solid column indicate the frequencies of TCR Vα/Vβ repertoires in the lung tissue and the 
peripheral blood lymphocytes (PBLs), respectively. We found that the usage of repertoires of 
TCR Vα/Vβ in the lung differed from those in PBL, with certain TCR V gene families detected 
more frequently from lung tissue. In patient A, TCR repertoires of VA2.1, VA8.1, VB4.1, and 
VB24.1 were predominantly expressed in the lung compared to PBL, while TCR V reper-
toires VA23.1 and VB13.1 were more frequently expressed in lung tissue from patient B. As 
expected, no TCR signals were detected on normal lung tissue obtained from patients without 
IP using the same method (data not shown).
6.2.2. Discussion
IP associated with PM/DM is recognized as a critical complication due to its association with 
poor disease prognosis. In this study, we investigated T cells infiltrates by analyzing the TCR 
repertoire usage in lung tissue in two patients with PM-associated early IP. Both patients 
showed marked lymphocytes aggregates, predominantly CD3+ T cells, at IP lesion sites. In 
addition, the analysis of TCR Vα/Vβ repertoire usage indicated a modest accumulation of 
T cells expressing selected TCR V-gene segments, which differed distinctly from those of 
PBL. These findings strongly suggest pathogenic involvement of organ-specific oligoclonal 
T cell accumulation in development of PM-associated IP. Since TCR diversifies with disease 
progression due to the phenomenon of “determinant spreading” in which autoreactive T cell 
responses, initiated by a single antigenic epitope, evolve into multiepitopic responses, we 
considered it important to perform TCR analysis from lung tissue in the earliest stage of IP 
[162]. Regarding differences in predominant TCR V gene usage between the two cases, we 
suspect this is due to HLA differences. A previous study on lung TCR repertoire in patients 
with PM by Englund et al. reported selective TCR V gene usage, characterized by a panel of 
TCR-specific monoclonal antibodies on flow cytometry [163]. However, that study used BAL 
fluid rather than lung tissue in which infiltrating T cells may be more directly involved in the 
disease process. Although we also tried to analyze TCR repertoire from BAL fluid, the data 
were inconclusive due to lack of TCR signals along with background noise from RNA debris. 
To our knowledge, this is the first robust demonstration of the presence of selective TCR V 
gene usage and its differential expression in lung tissues of patients with PM using both lung 
biopsy tissue from early IP and PBL. Because our study involved only two cases, these find-
ings should be confirmed in a larger study. However, we believe these findings strongly sug-
gest that T cells which are recruited into the lung may be exposed to autoantigens, selectively 
expanding by antigen-driven responses. Further studies are needed to identify T cell epitopes 
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Figure 3. (a) Quantitative analysis of TCR repertoires: TCR Vα gene usage (top) and TCR Vβ gene usage (bottom) in 
patient A. Solid and open bars indicate frequencies of TCR Vα/Vβ repertoires in PBL and lung tissue, respectively. VA2.1 
and VA8.1 and VB4.1 and VB24.1 repertoires predominate in lung tissue compared with PBL. (b). Quantitative analysis 
of TCR repertoires: TCR Vα gene usage (top) and TCR Vβ gene usage (bottom) in patient B. Solid and open bars indicate 
frequencies of TCR Vα/Vβ repertoires in PBL and lung tissue, respectively. VA23.1 and VB13.1 repertoires are more 
frequent in lung tissue compared with PBL.
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of the pathogenic antigens, which may potentially lead to the development of antigen-specific, 
molecular-targeted therapies, such as the induction of anergy by peptide analogues similar in 
structure to culprit antigens [164, 165].
Thus, as a result, the T cell receptor (TCR) repertoire study combined with histological analy-
sis demonstrated substantial CD3+ T cell lung infiltrates with specific oligoclonal TCR usage 
that differed from those in PBL, suggesting a pivotal role for T cells in the pathogenesis of 
PM-associated IP via antigen-driven immune mechanisms.
7. Management of interstitial pneumonia associated with connective 
tissue disease
Because of the wide variation in manifestations of ILD in the autoimmune disease of CTD, 
no simple management strategy is adequate for every possible clinical setting. While a part 
of patients with CTD-associated ILD have limited and stable disease, not always requiring 
treatment, the significant proportions have severe and progressive disease which necessitates 
prompt and appropriate treatment. Essentially, nevertheless, general therapeutic principles in 
CTDs can be applied to many situations including acute and chronic disease. These include 
use of corticosteroids, azathioprine (AZA), cyclophosphamide (CYC), methotrexate (MTX), 
mycophenolate mofetil (MMF), and calcineurin inhibitors [13]. Although there are no spe-
cific guidelines for the management of CTD-ILD, general strategies recommended for IPF 
of IIP are also often applied in some cases of CTD-ILD. Emerging treatments with effects in 
IPF, e.g., Pirfenidone (a pyridine showing both anti-inflammatory and anti-fibrotic effects) 
and Nintedanib (a small-molecule tyrosine kinase inhibitor targeting VEGF-, FGF-, PDGF-
receptors) may offer additional treatment options, though the efficacy has not been evaluated 
in CTD-ILD [166]. Basically, in contrast to the dismal prognosis in IPF/UIP of IIP with a median 
survival since diagnosis of 2–3 years, clinical experience in managing patients has taught us 
that immunosuppressive drugs in CTD-associated ILDs are capable of benefiting a significant 
proportion of patients, particularly those with certain histological patterns of disease.
With regard to the clinical study, there have been only two randomized placebo-controlled 
trials investigating the effect of immunosuppressive treatment in SSc-associated ILD. Briefly, 
the Scleroderma Lung Study (SLS) and the Fibrosing Alveolitis Scleroderma Trial (FAST), 
evaluated CYC (given orally at 2 mg/kg for 1 year in SLS and intravenously at a dose of 
600 mg/m2 monthly for 6 months, followed by oral AZA for the following 6 months in FAST) 
for SSc-ILD [72, 73]. Both studies found a slower decline in forced vital capacity (FVC) in the 
CYC group compared with placebo. Intravenous CYC elicited a lower rate of bone marrow 
toxicity, severe infections, and gonadal failure compared to oral administration, likely due 
to higher cumulative dose acquired by daily oral administration [167]. Six months after quit-
ting of immunosuppressant, the recovery in FVC fell into baseline, suggesting the require-
ment of prolonged immunosuppression therapy to maintain stability of lung function [168]. 
However, it should be noted that, despite studies supporting the benefit of CYC therapy in 
preventing deterioration in the lung function and premature death in patients with SSc–ILD, 
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recent systematic review and meta-analysis of RCTs and observational prospective cohort 
studies failed to validate any clinically significant improvement in pulmonary function in SSc 
patients treated with CYC [169, 170].
In PM/DM-associated ILD, high-dose steroid is often the first-line drug, although no definite 
therapeutic recommendation for the disease has been established yet. The other drugs most 
frequently used are AZA, MMF, hydroxychloroquine, MTX, CYC, and calcineurin inhibitors, 
e.g., cyclosporine A (CSA) and tacrolimus (TAC). Rituximab, anti-CD20 monoclonal antibody 
therapy, has lately emerged as a promising remedy of biologics in patients who have failed 
conventional immunosuppression treatments [171, 172]. Among a variety of immunosup-
pressants, the efficacy of calcineurin inhibitors for the treatment of PM/DM-associated ILD 
should be highlighted. CSA, which inhibits T cell proliferation and T cell-mediated cytokine 
productions at the transcriptional level, has begun to be used for PM/DM-ILD since the 1980s 
[173–175]. In 1998, the first nation-wide survey for the treatment with CSA in IP associated with 
CTDs was conducted in Japan, and the efficacy of a combination therapy with CSA and cortico-
steroids in PM/DM associated IP was indicated [176]. A number of retrospective and open-label 
studies have supported the benefit of CSA for the treatment of ILD with PM/DM [177–181]. 
Takada et al. published a retrospective multicenter study of 38 cases with acute ILD with PM/
DM, whereas it was shown that the combination therapy with CSA and corticosteroids started 
from the early phase of ILD is superior to corticosteroid monotherapy [178]. Today, calcineurin 
inhibitors are widely used especially in Japan as both an induction and maintenance therapy 
for PM/DM-ILD, generally resulting in favorable prognostic outcomes. The appropriate serum 
concentration of CSA to ensure a maximal effect as well as to avoid toxicity in patients with 
PM/DM-ILD should reach approximately 150 ng/mL and1000 ng/mL, at trough and at 2 hours 
after administration, respectively [179]. Another calcineurin inhibitor, TAC, which is a 100-
fold potent T cell inhibitor compared to CSA, was also introduced into the treatment for PM/
DM-ILD, and its efficacy and tolerability have been demonstrated in retrospective studies and 
case series since the report by Oddis et al. in 1999 [182–185]. Ochi, et al. described a superior 
effect of TAC used in two myositis patients with progressive ILD who failed CYC and cortico-
steroid treatment but successfully recovered with TAC, showing significant improvement in 
symptoms and radiologic changes [183]. The appropriate tacrolimus trough level for the treat-
ment of ILD in PM/DM patients have not been established by clinical trials, but it is usually set 
as 5–20 ng/mL on the basis of data from renal and bone marrow transplantation [186].
Given the treatment-effect heterogeneity of the lung disease observed in PM/DM, it is impor-
tant to prepare novel therapeutics for the challenging cases of ILD which are refractory to 
conventional formulas. Recently, Suda et al. reported the effectiveness of multitarget therapy 
for the ILD in two cases of anti-MDA5 antibody-positive DM which is known to be associated 
with progressive ILD and sometimes has a lethal outcome despite strong immunosuppressive 
therapy including CYC [187]. They used TAC and mizoribine (MZR, an inosine monophos-
phate dehydrogenase inhibitor) in combination with corticosteroids. MZR is a nucleoside of 
the imidazole class, with the same mechanism as MMF: selective inhibition of lymphocyte 
proliferation by blocking inosine monophosphate dehydrogenase [188]. The safety and ste-
roid-sparing effects of MZR have been shown in various CTDs, and the efficacy of multitarget 
therapy using TAC and MZR was reported for systemic lupus erythematosus [189, 190].




Despite increased recognition of CTD-associated ILD and its prognostic significance, the 
pathologic mechanisms that lead to the considerable pulmonary changes are not yet fully 
defined, and thus, the only limited progress has been so far made in the therapeutic domains. 
Immunosuppression therapy remains the mainstay of treatment for CTD-ILD. To generate 
significant advances in therapeutic intervention strategy, fundamental understanding of the 
pathogenesis of CTD-ILD is essential. As noted, we had an opportunity to carefully study the 
cases of early-stage IP associated with PM by utilizing lung biopsy tissue and PBLs. The T cell 
receptor (TCR) repertoire study combined with histological analysis demonstrated substantial 
CD3+ T cell lung infiltrates with specific oligoclonal TCR usage that differed from those in PBL, 
suggesting a pivotal role for T cells in the pathogenesis of PM-associated IP via antigen-driven 
immune responses. The results imply potential elucidation of specific antigen(s) that oligoclonal, 
lung-infiltrating T cells recognize, which may provide novel insights into the development of 
immunospecific treatments such as molecular-targeted or specific T cell-targeted therapeutics.
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